Medical Association. The Advisory Committee had the right not only to advise on how to proceed with the study, but also to stop it if any severe adverse effects occurred or the rates of clinical events differed greatly between the 2 groups. All the enrolled patients gave written informed consent.
Subjects and Follow-up
Inclusion criteria of the study were (1) aged less than 70 years, (2) at least 1 bypass graft, (3) no significant stenosis of the graft detected by CAG within 1 year post operation and (4) total cholesterol (TC) concentration between 180 and 269 mg/dl. We excluded patients with severe hepatic or renal dysfunction, stroke within the previous few months or a prior history of adverse effects with statin treatment.
The angiographic evaluation in the Cholesterol-lowering Atherosclerosis Study (CLAS) 18 showed a progression rate of 39% in the medicated group and 61% in the control group. Therefore, we assumed that we needed a sample size of 150 for each group to fulfill the precondition of =0.05 (2-sided), =0.10, in consideration of those cases that would not be assessable because of a decision by the Evaluation Committee members that they were inappropriate and should not be followed up.
Prior to enrollment, patients were tentatively registered at the time of CABG to evaluate their eligibility and on confirmation of the non-existence of significant stenosis in the bypass graft by CAG, they were randomly assigned to either the pravastatin group or the control group by the minimization method, stratified by the institution, TC concentration (4 classes of 181-199, 200-219, 220-239, 240-269 mg/dl) and presence/absence of risk factors (hypertension, diabetes mellitus (DM) and hyperuricemia). Hypertension was defined as blood pressure ≥140/90 mmHg and/or the use of anti-hypertensive agents; DM was defined as a fasting blood sugar concentration ≥140 mg/dl and/or the use of diabetes medication; hyperuricemia was defined as a plasma uric acid concentration ≥7.0 mg/dl and/or the use of anti-hyperuricemic agents. Additionally, hypercholesterolemia was defined as a serum TC concentration ≥220 mg/dl. Pravastatin was administered at a dose of 10-20 mg/day to the pravastatin group, and all lipid lowering agents were prohibited in the control group. Patient enrollment was from August 1991 to March 1994. The enrolled patients were scheduled for monthly visits to the participating institution where their compliance with the treatment regimen, clinical events and adverse effects were evaluated throughout the follow-up term. They also underwent laboratory tests of TC, triglycerides and high-density lipoprotein cholesterol (HDL-C) at the participating hospital at least once a year; low-density lipoprotein-cholesterol (LDL-C) was calculated using Friedewald's method. 19 The expected follow-up term was 5 years. Follow-up CAG was performed 3-7 years after enrollment to assess the progression of coronary atherosclerosis. If any cardiac event occurred, CAG was performed and evaluated at that time. Cholesterol-lowering drugs were administered to patients in the control group if the TC concentration exceeded 270 mg/dl.
Angiographic Evaluation
The baseline and follow-up CAG was performed using a standard technique for quantitative coronary angiogram (QCA) analysis. 20 Nitroglycerin or isosorbide dinitrate was administered before angiography. The angiograms obtained in each institution were evaluated by the independent Angiogram-Reading Core Laboratory. One pair of matched end-diastolic frames in which every lesion was best seen was selected from the baseline and follow-up angiograms.
Quantitative assessment was performed by trained operators in the Angiogram-Reading Core Laboratory unaware of the patient's details. The 3 segments that each graft was divided into, excluding the anastomotic sites, and the 15 segments of the native coronary arteries according to the American Heart Association classification were evaluated. The minimum luminal diameter (MLD), mean segment diameter (MSD) and percent diameter stenosis (%DS) of the graft and native coronary artery were measured using QCA-CMS (MEDIS, the Netherlands). The mean value of each of the QCA parameters in each patient was used as individual data in the analysis.
In the visual assessment, the %DS and the global change score (GCS), as reported in the CLAS by Blankenhorn et al, 18, 21 was used. Briefly, pairs of films showing identical views with their temporal order masked were evaluated by 2 expert angiographers of the Angiogram Reading Committee who were unaware of the patient's details. They independently recorded their findings of the native coronary arteries and grafts diagrammed in one of the films, each identifying the lesions and %DS of each segment and assessing them using an 11-point grading system. 22 They reached a consensus regarding the degree and location of all stenotic lesions in that film. For the other film of the pair, they evaluated all the diagrammed lesions as well as new ones. If there was any change, a new degree of stenosis was estimated. Each angiographer recorded a global evaluation of the films on a 4-point scale that combined the changes in both the grafts and native coronary arteries. A score of 0 indicated no demonstrable change; 1, definitely discernible change; 2, intermediate change; and 3, extreme change. Working independently, they also recorded which film exhibited the greater extent and severity of obstructive atherosclerosis in the native coronary arteries and/or abnormality of the grafts. Given the temporal order of the film later, they attached a plus (progression) or minus (regression) symbol to the GCS. As a last step, the pair of angiographers reviewed and discussed both films together. A consensus was recorded about the change in each lesion, the percent stenosis for new lesion, and agreement as to which film showed the greater extent of lesions in the native coronary arteries and/or grafts. The consensus GCS, which was the overall judgment by both angiographers integrating all changes evaluated from the film pair, was the per-patient analysis reported in this study.
Clinical Outcome
The clinical outcomes, including cardiac death, non-fatal myocardial infarction, angina pectoris, heart failure, death from stroke, cerebral infarction, transient ischemic attack, coronary angioplasty and redo bypass surgery were evaluated by an independent Clinical-Event Confirmation Committee, with the treatment assignment and institution masked.
Statistical Analysis
Statistical differences between the values obtained in the 2 groups were analyzed by the Wilcoxon rank sum test for quantitative data and chi-square test for categorical data. Cumulative event rates for the clinical outcomes were estimated by Kaplan-Meier method. The log-rank test was used to compare the event-free survival curves and the 2-way repeated measures ANOVA method was used to compare the data with temporal change. For these analyses, SAS version 6.12 software was used (Cary, NC, USA). The p-values in the statistical analyses were 2-sided, and p<0.05 was considered to be significant.
Results

Baseline Characteristics of the Patients
A total of 335 patients who fulfilled the entry criteria were enrolled: 168 and 167 in the pravastatin and control groups, respectively (Fig 1) . Of these, 32 cases were excluded from follow-up, so the final numbers of the pravastatin and control groups were 152 and 151, respectively, giving a total of 303 cases for the baseline and clinical event analyses. Of the 303 cases, 96 patients did not undergo repeat CAG and 25 patients were not analyzed because of the inadequate quality of the cine-angiograms. Thus, paired coronary angiograms were obtained at baseline and during follow-up in 182 (60%) patients, of which 96 in the pravastatin group and 86 in the control group were used for the visual assessment. As QCA was impossible in 16 cases, 88 in the pravastatin group and 78 in the control group (166 in total) were used for QCA.
There were less male subjects in the pravastatin group than the control group with 80.3% and 88.1%, respectively (p=0.06) ( Table 1) . No significant differences were observed between the 2 groups in age, body mass index, previous myocardial infarction, family history of coronary artery disease, the prevalence of comorbidities or concomitant medication. The mean concentrations of TC, LDL-C and HDL-C were almost the same between the 2 groups, and no significant difference was noted in the triglyceride concentrations.
Furthermore, there were no significant differences in the number of affected vessels, left ventricular ejection fraction or number of bypass grafts (Table 2) .
Follow-up
No significant difference was observed in the mean follow-up of each group: 4.5±0.8 years in the pravastatin group and 4.4±1.1 years in the control group. 
Compliance
In the pravastatin group 97% took the mean dose of 9.1± 4.2 mg/day; however, the compliance was less than 75% throughout the follow-up term in 19% of the pravastain group, and furthermore, 5% of them took other medicine that had been prohibited by our protocol from concomitant use with pravastatin. In the control group, 32% took lipidlowering medications and 26% of them took pravastatin.
Cholesterol Concentrations
The TC concentration significantly decreased from 213.7
to 186.4 mg/dl (-12.8%) in the pravastatin group (p<0.001), but showed no change in the control group (p=0.75) (Fig 2) , which was a significant difference between the 2 groups (p<0.01). A significant difference was also observed between the 2 groups in the LDL-C concentration (p<0. 
QCA Evaluation
No significant difference was observed between the 2 groups in the changes in the MLD or the MSD of the saphenous vein graft (SVG) ( Table 3) . Furthermore, no significant difference was observed in the %DS between the 2 groups, which was also the case with changes in the MLD, the MSD and the %DS of the internal mammary artery (IMA) graft as well as the native coronary artery.
Visual Assessment
A significant difference was observed in the GCS evaluation: the mean score of 0.77±1.17 (SD) and 1.23±1.32 in the pravastatin and control groups, respectively (p<0.01) (Fig 3) . The rate of the patients evaluated as score 2 or 3, which indicated worsening to moderate or severe during the follow-up term, was 24% and 49% of the patients in the pravastatin and control groups, respectively.
The mean change in the %DS of the SVG in the pravastatin group was 14.6±30.2%, which was lower than that in the control group of 20.0±29.5, although not significant (p=0.07) (Table 4) . Furthermore, when low compliant cases were excluded, change of the %DS in the pravastatin group was significantly lower than that in the control group (16.6±31.5 vs 22.6±29.4, p=0.04). On the other hand, no difference was observed between the 2 groups in the %DS changes of the IMA graft and the native coronary artery, whether low compliant cases were excluded or not.
Clinical Events
Cardiac events including cardiac death, myocardial infarction and recurrent angina pectoris, heart failure, percutaneous transluminal coronary angioplasty and repeat CABG were observed in 23 cases (15.1%) of the pravastatin group and in 31 cases (20.5%) of the control group (Table 5) . Cerebrovascular events were also observed in 1 case (0.7%) of the pravastatin group and in 6 cases (4.0%) of the control group. Six patients (3.9%) in the pravastatin and 11 (7.3%) in the control group died in the course of the study. The incidence rates of all cardio/cerebrovascular events were 17.1% and 23.8% in the pravastatin and con- trol groups, respectively, showing a 30% reduction in the pravastatin group, although not significant (p=0.17) (Fig 4) .
Adverse Effects
Thirty-one adverse incidents were reported in 14 cases from the pravastatin group, of which 3 incidents in 1 case could not be denied as related to the drug. They were slight elevation of creatine phosphokinase and lactate dehydrogenase, both of which were recognized as grade 1.
Discussion
We investigated the effect of pravastatin on the progression of atherosclerosis in the SVG and IMA grafts and the native coronary arteries after CABG. The TC and LDL-C concentrations in the pravastatin group significantly decreased by 12% and 19% respectively, whereas those in the control group showed no significant change. Although no significant difference was observed between the 2 groups in the QCA analyses, a significant retardation of progression was observed in the pravastatin group, according to the GCS, compared with the control group.
There are several explanations for the discrepancy between the QCA findings and the results of the GCS in the present study. The number of the paired cinefilms suitable for the QCA was limited because of some patients' refusal to undergo repeat angiography. Furthermore, inadequate control of angiographic quality for the QCA also influenced the equivocal results. Insufficient amounts of contrast media as well as the presence of metal clips used for hemostasis of the side-branches of the grafts also made accurate measurements by the QCA difficult. In addition, over the long course of the study, CAG techniques, angiographers and even the CAG machines in some institutions have changed. Consequently, the number of total segments analyzed by QCA was only 35% of those analyzed by visual assessment, which we consider is the main reason for the discrepancy between the 2 assessment methods.
Despite the results of the QCA in the present study, the GCS, by which atherosclerotic changes in the whole coronary artery tree including bypass grafts were analyzed, indicated a significant inhibition of atherosclerotic progression by pravastatin. Furthermore, the fact that changes in the %DS of the SVG appeared to be lower in the pravastatin group compared with the control group suggests that the major cause of the GCS difference can be attributed to the anti-atherosclerotic effect of pravastatin in the vein graft. Moreover, despite the absence of a significant difference between the 2 groups, analysis of the clinical event-free survival rate showed a 30% reduction in the pravastatin group (Fig 4) with a temporal increase, suggesting that a significant difference could occur with a longer follow-up period and consequently some clinical benefit of pravastatin. The magnitude of the event reduction was similar to that observed in the post CABG trial. 13 Thus, we believe the results of the present study suggest a potential clinical benefit of pravastatin in Japanese post-CABG patients.
Comparison With Previous Studies
Several previous trials have examined the effects of lipid-lowering drugs in post CABG patients. The CLAS demonstrated less progression in the native coronary arteries as well as the SVGs in post-CABG males randomly assigned niacin and cholestipol than in those assigned placebo. 18, 21 In the Post Coronary Artery Bypass Graft Trial (Post CABG trial), 15 aggressive lipid lowering using lovastatin with or without cholestipol suppressed the progression of atherosclerosis in the SVGs as well as in the native coronary arteries. In the Lopid Coronary Angiography Trial (LOCAT) 16, 17 found that gemfibrozil retarded the progression of coronary atherosclerosis and formation of bypass graft lesions in post-CABG males with low HDL-C concentrations. The results of the present study support these previous demonstrations that lipid modification has the potential for delaying the progression of coronary atherosclerosis in Japanese post-CABG patients, too.
Among the angiographic trials of CABG patients, the present study was designed to investigate the effect of statin therapy administered shortly after CABG. Although one of the inclusion criteria of the present study was having CABG within 1 year of beginning statin treatment, 67% of the patients had undergone surgery within 3 months. The patients enrolled in the previous studies included only those more than 3 months after CABG (CLAS), 18,21 3-48 months after CABG (LOCAT) 16 and 1-11 years after CABG (Post CABG). 15 No prior studies have specifically investigated the efficacy of early statin therapy on angiographic progression after CABG. Saphenous vein graft stenosis occurs through different mechanisms at different periods of time after operation; early perioperative thrombotic occlusion occurs within 3 months after surgery, intimal thickening and proliferation within 2-3 years and late degeneration from atherosclerosis. 23, 24 In the present study, we investigated post-CABG patients from the early postoperative period to 5 years after operation, focusing on newly developed graft lesions as well as concomitant arteriosclerotic progression in the native coronary artery. The inhibitory effect of pravastatin on both these parameters may be related to the combination of its anti-atherogenic, anti-thrombotic and anti-proliferative effects. [25] [26] [27] Considering the rather low initial TC concentration (214 mg/dl), poor drug compliance in both groups and comparatively small dosage (9.1 mg/day) of pravastatin than in the other studies, our results suggest that early initiation of pravastatin medication to post-CABG patients may be beneficial not only for delaying the progression of coronary atherosclerosis, especially in the SVG, but also for reducing the clinical event rate.
Study Limitations
1. A new regulation called the Good Post Marketing Surveillance Practice was introduced into Japan in 1993, which was during the enrollment period, and caused delayed patient enrollment and lengthened the study period, as well as suspended the strict follow-up of the study for some time. It was the main reason for the poor compliance and low rate of follow-up CAG. 2. This study was not designed to detect a significant difference in the clinical-event rate. Significant difference could have only been obtained if the number of enrolled patients had been much larger, and/or the duration of the study had been much longer. 3. The LDL-C concentration in the pravastatin group remained at 113.7 mg/dl, which was rather high for the recent tendency for aggressive lipid-lowering treatment. It was not the case in the early 1990s. If drug compliance had been better and a higher dose of pravastatin had been administered, a significant difference may have been obtained in the clinical-event rate.
Conclusion
The present study has demonstrated only a marginal beneficial effect of LDL lowering on the progression of coronary atherosclerosis in patients after CABG operation. However, when the results of previous studies are taken into consideration, the present results suggest that pravastatin has the potential to reduce atherosclerotic progression, particularly in the SVG, in post-CABG patients.
